Loading...
Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset fro...
Na minha lista:
| Udgivet i: | Ther Adv Neurol Disord |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4784254/ https://ncbi.nlm.nih.gov/pubmed/27006700 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616628766 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|